Anti-alpha beta TCR binding polypeptides with reduced cleavage

• Main Author: QIU HUAWEI
• Format: Patent
• Language: Chinese; English
• Published: 24.06.2025
• Subjects: CHEMISTRY; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES

The present invention relates to anti-[alpha] [beta] TCR binding polypeptides with reduced cleavage, as well as improved compositions and methods for treating T cell mediated diseases and disorders (e.g., autoimmune disorders, graft versus host disease, and graft rejection). An anti-[alpha] [beta] TCR binding polypeptide is provided, including an antibody, comprising at least one amino acid substitution or modification that increases the stability of the binding polypeptide by reducing the cleavage of the light chain variable region. The methods provided herein generally involve administering to a subject in need thereof an effective amount of a stabilized humanized binding polypeptide having specificity for alpha beta T cell receptor (alpha beta TCR). 本发明涉及具有降低的断裂的抗αβTCR结合多肽，以及改进的用于治疗T细胞介导的疾病和障碍(例如，自身免疫障碍、移植物抗宿主病和移植物排斥)的组合物和方法。提供了包括抗体在内的如下抗αβTCR结合多肽，其包含至少一个氨基酸取代或修饰，所述至少一个氨基酸取代或修饰通过降低轻链可变区的断裂来增加所述结合多肽的稳定性。本文提供的方法总体上涉及向有需要的受试者施用有效量的对αβT细胞受体(αβTCR)具有特异性的稳定化人源化结合多肽。